Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : CDMA, Globalstar versus Iridium, Inmarsat, etc. -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (335)	12/3/1997 3:59:00 PM
From: Pseudo Biologist	Respond to of 381

[Off-topic p53] Maurice, sorry for the delay, but I do have some information. First, I had downloaded the Blood paper a few weeks ago but still have not found the time the give it justice. From other reading on p53 I'd say your engineer's take on the issue is not far off the mark. Second, Affymetrix signed a deal with an outfit called Oncormed to do p53 testing for cancer diagnostic/prognostic purposes. I read somewhere that this is being marketed by Oncormed, but I have not tried to confirm this yet. Worth a look. Rituxan launched in Switzerland today. Good luck with CHOP and best wishes. PB

To: Maurice Winn who wrote (335)	12/3/1997 6:48:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 381

[more off-topic p53] Maurice, this is a recent release from Affymetrix/Oncormed that mentions the p53 gene chip; go to the end of the release to see what's going on. In short, Affymetrix is already selling it for research purposes, while Oncormed is working on getting it approved for diagnostic purposes. biz.yahoo.com PB